BioCentury
ARTICLE | Editor's Commentary

Makary facing key test: a Perspective

The FDA commissioner must swiftly reverse decision to conduct a political review of a COVID vaccine — or risk irreparable damage to FDA’s credibility

April 5, 2025 12:41 AM UTC

Credibility is earned by the drop and lost by the bucket. FDA Commissioner Marty Makary is on the verge of kicking over the bucket.

In his first days as commissioner, he allowed Principal Deputy Commissioner Sara Brenner to put an 11th-hour hold on the approval of a COVID-19 vaccine from Novavax Inc. (NASDAQ:NVAX). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article